We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PROVENT

News List

AZD7442 reduces COVID-19 risks by 83 percent in Phase III trial EuropeanPharmaceuticalReview
November 26, 2021
AstraZeneca has announced new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials which both showed robust efficacy from a one-time intramuscular...
Intravacc Completes Project for Provention Bio’s Vax Candidate contractpharma
January 20, 2021
Contract development and manufacturing organization (CDMO) Intravacc, said that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in ...
Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 americanpharmaceuticalreview
January 06, 2021
Provention Bio announced the initiation of PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B (CVB) vaccine candidate, PRV-101.